Orchestra BioMed is a New Hope partnership shop whose equity is a residual claim on two cardiovascular devices that larger manufacturers are supposed to sell. The second quarter closed the last scheduled partner checks and left the BACKBEAT hypertension-pacing study pointed at a late-breaker in the second quarter of 2027. That is the entire investment debate for this equity. The market is being asked to treat Medtronic-grade distribution as the path that turns firmware modulating atrioventricular timing into a royalty stream large enough to justify a mid-triple-digit-million enterprise value before cash thins later in the planned runway.
Partner capital of $35 million arrived in May from Medtronic and Ligand. Combined cash and marketable securities sat at $110 million at quarter-end. Management states that stack funds operations into the fourth quarter of 2027 if recent burn holds. Those same contracts already sold a slice of the future. Ligand holds a tiered revenue interest and Medtronic holds a note that converts into a prepaid revenue share on approval. The residual claim is thinner than the headline cash figure implies.
Second-quarter research spending rose as BACKBEAT and the Virtue balloon program both enrolled patients. Operating cash use reached $19.6 million in the quarter. Net loss attributable to common holders was $24.1 million. The question the next year resolves is whether BACKBEAT's blood-pressure endpoint clears the bar that turns Medtronic from a capital partner into a commercial engine, or whether the equity is left funding a single remaining balloon trial against an already-encumbered royalty stack.